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ABSTRACT 
Peritoneal Carcinomatosis (PC) is a severe form of cancer in the abdomen, currently treated 
with cytoreductive surgery (CRS) and intravenous (IV) chemotherapy. Recently, nebulization 
has been proposed as a less invasive strategy for the local delivery of chemotherapeutic drugs. 
Also, RNA interference has been considered as a potential therapeutic approach for treatment 
of cancer. In this study, Lipofectamine® RNAiMAX/siRNA complexes and cyclodextrine/ 
siRNA complexes were evaluated before and after nebulization. Nebulization of the siRNA 
complexes did not significantly lower transfection efficiency when compared to non-nebulized 
complexes. After incubation in ascites fluid, however, the cyclodextrine/ siRNA complexes 
showed a drastic decrease in transfection efficiency. For the Lipofectamine® RNAiMAX/ 
siRNA complexes, this decrease was less pronounced. We conclude that nebulization is an 
interesting technique to distribute siRNA complexes into the peritoneal cavity, providing the 
complexes are stable in ascites fluid which might be present in the peritoneal cavity.  
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INTRODUCTION  
 
Peritoneal Carcinomatosis (PC) is a severe form of cancer with a complicated pathogenesis 
and poor prognosis1,2. It often results from a primary tumor of organs within the abdomen, such 
as the ovaries and colon1. In the process of dissemination, cancer cells first detach from the 
primary tumor. Then, they attach to the peritoneal mesothelium followed by infiltration into the 
interstitial space, proliferation and the development of new vasculature3.  
Current treatment of peritoneal carcinomatosis implies cytoreductive surgery to remove 
all visible tumor cells, followed by intravenous (IV) chemotherapy to eliminate the remaining 
tumor nodules in the peritoneal cavity4,5. Alternatively, intraperitoneal chemotherapy is being 
used, through which drugs are locally administered into the peritoneal cavity to enhance drug 
exposure to the tumor metastases and lower the systemic toxicity6,7. Also, higher drug 
concentrations are expected to reach avascular tumors in comparison with IV administration8,9.  
Recently, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is used as a novel drug 
delivery method in the treatment of peritoneal carcinomatosis. In PIPAC, chemotherapeutic 
drugs are nebulized throughout the peritoneal cavity by applying a high pressure (~20 bars), 
ensuring a homogenous distribution of small aerosol particles of the drug10,11. PIPAC is thought 
to enhance the therapeutic index by local administration into the abdomen, is a minimally 
invasive technique and has the ability to overcome the elevated interstitial fluid pressure in 
tumor nodules by applying high-pressure7,10,11.  
Currently, PIPAC is evaluated in the clinic for nebulization of chemotherapeutics such 
as cisplatin and oxaliplatin. Apart from chemotherapeutics, however, also the use of nucleic 
acids has the potential to treat peritoneal carcinomatosis12. In RNA interference (RNAi), small 
interfering RNAs (siRNAs) can be used to downregulate cancer-associated genes. The short 
double stranded RNA molecules composed of 21-23 nucleotides result in the cleavage of 
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specific mRNA molecules, leading to a decrease in protein expression13. In contrary to 
conventional chemotherapy, a specific targeting of tumor cells can be obtained14. In order to 
knockdown a specific gene, siRNAs should be delivered into the cytoplasm of the cells15. 
Nevertheless, naked nucleic acids are relatively unstable, sensitive to enzymatic degradation by 
nucleases and quickly eliminated through filtration by the kidneys16. Additionally, due to the 
hydrophilic nature and anionic charge, almost no intracellular uptake occurs due to the poor 
interaction with the cellular membrane12,16.  
To enhance the transfection efficiency, appropriate delivery vehicles are needed to 
deliver siRNA into the cells12,16. Especially nanoparticles have gained interest in the field of 
gene delivery since they can facilitate the uptake of nucleic acids into cancer cells and provide 
the possibility of targeting specific cell types. In general, positively charged carriers interact 
with the negatively charged nucleic acids, leading to the formation of complexes based on 
electrostatic interactions. Both lipid-based carriers and polymer-based carriers are used, leading 
to the spontaneous formation of respectively lipoplexes or polyplexes17.  
Nanoparticles encounter several extracellular and intracellular barriers before siRNA is 
efficiently delivered into the cytoplasm where it can exert its function18. Extracellularly, the 
nanoparticles have to ensure that the siRNA remains undamaged when circulating through the 
body. When developing nanocarriers for intraperitoneal delivery, stability in the extracellular 
fluids is an important requisite19. Proteins in the blood and ascites fluid may, however, lead to 
a premature siRNA-release and/or aggregation of the particles4,19. When nanoparticles interact 
with the cell membrane they are mostly taken up by endocytosis. Then, endosomal escape 
should occur to avoid lysosomal degradation and release the siRNA into the cytoplasm where 
it can exert its function. Clearly, all these barriers might influence the biological activity of 
siRNA containing nanoparticles.  
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In this work, we focused on two different nanocarriers, namely the lipid-based 
Lipofectamine® RNAiMAX and a polycationic amphiphilic cyclodextrin termed as ADM70 
(CD ADM70). Cyclodextrins (CDs) are a family of cyclic oligosaccharides and composed of 
α-(14)- linked d-glucopyranose units20-22. The cyclodextrin used in this study belongs to the 
family of polycationic amphiphilic cyclodextrins (paCDs) and consists of thiourea segments, 
polycationic clusters and lipophilic tails as described before21,23,24. The thiourea segments 
together with the polycationic clusters are used to efficiently complex nucleic acids such as 
siRNA21,23,24. The resulting complex is positively charged, facilitating the interaction with the 
negatively charged cell membrane and cellular uptake24. Using both carriers, we evaluated 
whether high pressure nebulization of the resulting siRNA containing nanoparticles has an 
effect on their biological activity. Therefore, the transfection efficiency of siRNA complexes 
was evaluated on a SKOV-3 cell line before and after nebulization. Furthermore, the influence 
of ascites fluid on the efficiency of the siRNA complexes was studied after a 1-hour incubation 
period, to evaluate the stability of the complexes in this biofluid that might be present in patients 
with peritoneal carcinomatosis25.
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EXPERIMENTAL SECTION 
 
Materials 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased from Sigma Aldrich 
(Bornem, Belgium). Penicillin-Streptomycin (5000 U/ml), Lipofectamine® RNAiMAX 
Transfection Reagent, L-Glutamine (200 mM), 0.25% Trypsin-EDTA (1X) Phenol Red, 
McCoy's 5A (Modified) and Opti-MEMTM were purchased from Invitrogen (Merelbeke, 
Belgium). The cyclodextrin ADM70 was synthesized as described elsewhere24. Luciferase 
Assay Substrate was purchased from Promega (Madison, WI, USA). Fetal Bovine Serum (FBS) 
was purchased from HyClone® Thermo Scientific (Cramlington, UK). Passive Lysis Buffer and 
Luciferase Assay Kit were purchased from (Promega, Leiden, Netherlands). The ascites fluid 
was obtained from a peritoneal carcinomatosis patient at the Ghent University Hospital, as 
approved by the ethical committee of the Ghent University Hospital (no. 2013/589).  Negative-
control siRNA (siNEG) and luciferase siRNA (siLuc) were purchased from Eurogentec 
(Searing, Belgium) and diluted in 250 µL RNAse free water to a final concentration of 20 µM.  
 
Complex preparation and characterization 
The RNAiMAX/siRNA complexes were prepared at different RNAiMAX (µl) to siRNA 
(pmol) ratios as follows: negative control siRNA or luciferase siRNA was diluted with Opti-
MEMTM (solution A). Then, the appropriate volume of RNAiMAX was added to Opti-MEMTM 
(solution B) and complexes were obtained by mixing equal volumes of solution A and B, 
followed by incubation at room temperature for 30 minutes. Ratios are expressed as volume of 
RNAiMAX used to complex 10 pmol siRNA, with N/P ratio 3 being recommended by the 
manufacturer. To prepare cyclodextrin/siRNA complexes at different N/P ratios, equal volumes 
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of a cyclodextrin-solution in HEPES buffer was added to a solution containing 1 pmol/µl of 
negative control siRNA or luciferase siRNA, and incubated for 30 minutes at room temperature. 
Different N/P ratios were made by changing the concentration of the cyclodextrin-solution, 
with a maximum of 0.42 mM to obtain N/P ratio 10. Throughout this paper, the cyclodextrins 
will be termed as ADM70.  
DLS measurements were performed using solely the firefly luciferase siRNA. 
RNAiMAX/siRNA complexes were prepared at N/P ratios of 2, 3, 4, 6 and 8 with a total volume 
of 100 µL and at a final concentration of 0.5 µM siRNA. ADM70/siRNA complexes were 
prepared at N/P ratios of 4, 6, 8 and 10 and at a final siRNA concentration of 0.5 µM. 800 µL 
of HEPES buffer was added to the complexes and the suspension was transferred to the zeta 
cell (Malvern cells, UK) with a 1 mL syringe (BD PlastipakTM, USA). All samples were 
prepared in a dust free laminar flow (LAF) and measurements were performed using a Zetasizer 
Nano-ZS (Malvern instruments, Worcestershire, UK) at 25°C. DLS measurements of 
complexes prepared in Opti-MEMTM or biological fluids are not possible since proteins and 
other macromolecules can interfere with the measurements19 
 
Agarose gel electrophoresis 
Gel electrophoresis was used to test at which N/P ratios stable complexes are formed. 1 
g agarose (Invitrogen by Life TechnologiesTM, Carlsbad, USA) was dissolved in 80 mL of 
heated deionized water. Next, the solution was diluted to a final volume of 100 mL with cold 
deionized water. 10 µL of gelred (Biotium, Hayward, USA) was added to the solution. The 
solution was allowed to cool to 50°C and poured into the gel holder. Samples for gel 
electrophoresis were prepared using firefly luciferase siRNA. RNAiMAX/siRNA and 
ADM70/siRNA complexes had a final concentration of 0.5 pmol/µl siRNA and N/P ratios of 
0; 0.5; 1; 2; 3; 4; 6; 8 and 0; 0.5; 1; 2; 4; 6, 8, 10 respectively. Then, 5 µL of loading buffer was 
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added to 20 µl of each sample. When stability of complexes in ascites fluid was evaluated, an 
incubation time of 20 minutes in 10 µL ascites was incorporated before addition of the loading 
buffer.   
 
Cell culture and transfection experiments 
In vitro transfections were performed in the human ovarian cancer cell line SKOV-3 which 
stably expresses firefly luciferase. Cells were cultured in McCoy's 5A medium supplemented 
with FBS, Penicillin-Streptomycin and L-Glutamine. Cells were cultured until 80% to 90% 
confluency and detached from tissue culture dishes with 0.25% trypsin. Cells were maintained 
in an incubator at 37°C in a humidified atmosphere with 5% CO2.  For the transfection 
experiments, SKOV3 cells were plated 24 h prior to the experiment into 24-well plates at 50000 
cells/well. Subsequently, each well was provided with the appropriate amount of complex 
solution in 500 µl Opti-MEMTM, corresponding to 1, 2, 5, 10,  25 or 50 pmol of siRNA per 
well. After 4 h incubation, the transfection medium was replaced by fresh culture medium. Each 
formulation (containing siRNA duplex firefly (siRNA luc)) was compared with its own control 
(containing siRNA pGL3 luciferase control (siRNA ctrl)). After 24 hours incubation, cells were 
lysed with Passive Lysis Buffer and analyzed for firefly luciferase expression using the 
luciferase assay kit (Promega). The luminescence (Relative Light Units, RLU) was measured 
using a GloMax Luminometer (Promega). The percentage of luciferase downregulation was 
determined by the following equation: % transfection = 100 – (100 x RLUluc/RLUctrl), where 
RLUctrl is the mean for control siRNA and RLUluc is the mean for luciferase siRNA.   
 
Complex nebulization 
To evaluate the effect of aerosolization on the physicochemical properties and transfection 
efficiency of the complexes, 300 µl of complexes (containing 0.5 pmol/µl siRNA) were 
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aerosolized using a Microsprayer® Aerosolizer in combination with a high-pressure syringe 
(Penn-Century, Wyndmoor, USA) as described before26. Aerosolized complexes were collected 
in Eppendorf vials (typically > 90% recovery). Then, the nebulized complex solutions were 
used for size and zeta potential measurements and for transfection experiments as described 
above. All transfection experiments were carried out in triplicate for each treatment to allow 
calculation of the standard deviation. 
 
Complex incubation in ascites fluid 
RNAiMAX/siRNA and cyclodextrin/siRNA complexes were prepared at a concentration of 0.5 
and 2.5 pmol/µl siRNA respectively. For the transfection experiments with an amount of 5 pmol 
and 25 pmol siRNA/well, 50 µL of these complex solutions was added to 50 µL ascites fluid. 
After 1-hour incubation at 37°C, 100 µL of the incubated solution was added to 400 µL Opti-
MEMTM in the well. For the RNAiMAX/siRNA and cyclodextrin/siRNA transfection with an 
amount of 10 pmol and 50 pmol siRNA respectively, 100 µL of the complex solution was added 
to 100 µL ascites. After 1-hour incubation at 37°C, the 200 µl mixture was added to 600 µL 
Opti-MEMTM in the well.   
 
Statistical analysis 
Statistical analysis was performed using Graphpad Prism 7 software, by using an 
analysis of variance (ANOVA) followed by the Sĭdák Multiple Comparisons test with an α-
value set at 0.05. For each formulation, the transfection efficiency before and after nebulization 
was compared.  
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RESULTS AND DISCUSSION 
Complex formation and stability in ascites fluid.  
As a first step in the characterization of siRNA containing complexes, a gel retardation assay 
was performed to determine the optimal N/P ratio for siRNA encapsulation. Also, the stability 
of the complexes was evaluated upon incubation in ascites fluid.  
Figure 1A depicts the complexation efficiency of RNAiMAX/siRNA complexes at 
different N/P ratios immediately after preparation in Opti-MEMTM. For the N/P ratio of 0, solely 
siRNA is loaded into the well. For N/P ratios 0.5 and 1, free siRNA (asterisk) can be detected 
on the gel, which is attributed to the low amount of Lipofectamine® RNAiMAX used to prepare 
these solutions. Starting from N/P ratio of 2, free siRNA is no longer detected and complexes 
appear in the wells of the gel (open circle). It seems that the amount of positive charges is 
sufficient to form electrostatic interactions with the majority of negatively charged siRNA 
starting from N/P ratio 2. When the N/P ratio is increased even more, the intensity of the 
complexes in the wells seems to increase. We hypothesize that the siRNA appears more bright 
as the fixed amount of siRNA is able to spread over a larger number of RNAiMAX liposomes, 
increasing their accessibility to the Gelred used to detect the siRNA. Figure 1B shows the 
complexation efficiency of the ADM70/siRNA complexes at different N/P ratios after 
preparation in HEPES buffer. In contrast to the Lipofectamine® RNAiMAX complexes, full 
complexation of siRNA is only visible at N/P ratio 6 while at N/P ratio 4 some complexes 
appear but also a smear of free siRNA is still noticeable on the gel. Upon increasing the amount 
of positively charged ADM70, however, more stable complexes are formed with the ability to 
fully complex siRNA.   
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Figure 1. Agarose gel electrophoresis of (A) RNAiMAX/siRNA complexes and (B) 
ADM70/siRNA complexes prepared at different N/P ratios as depicted above each well. 
The final amount was 10 pmol siRNA/well. A 100 basepair (bp) ladder is positioned in the 
last well. (C) and (D) represent the RNAiMAX/siRNA and ADM70/siRNA complexes 
following incubation in ascites fluid. (E) represent ascites fluid alone (first lane) and free 
siRNA (second lane). Open circle, arrowhead and asterisk point to the position of 
complexes, ascites fluid and free siRNA respectively.    
 
One of the objectives of this work is to study the stability and biological activity of the 
complexes in a relevant biological fluid for PC. Therefore, the complexation efficiency of the 
siRNA complexes was determined in ascites fluid obtained from a peritoneal carcinomatosis 
patient. It has already been suggested that a protein-rich environment can alter the identity of 
nanoparticles, leading to cargo release, aggregation, inhibition of uptake and decrease of 
biological activity19,27. When ascites fluid results in the release of siRNA from the complexes, 
this should be noticeable by the re-appearance of free siRNA in the gel. Figure 1C shows that 
free siRNA bands were observed for Lipofectamine® RNAiMAX complexes prepared with 
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N/P ratios 2, 3 and 4. A possible explanation for this siRNA release is the competition between 
siRNA and negatively charged proteins in the ascites fluid for binding to the carrier4,19. 
However, this is highly likely not a full release since clear staining in the wells is still visible 
and the band intensities are much less than the free siRNA control (Figure 1E). At N/P ratio of 
8 no free siRNA bands are present, implying a greater stability in comparison with the other 
N/P ratios. When ADM70/siRNA complexes are incubated in ascites fluid, no free siRNA is 
detected while complexes are seen in the wells (Figure 1D). It should be noted that the ascites 
fluid itself is also detected on the gel, but does not interfere with the interpretation of the siRNA 
band (Figure 1C-E, arrowhead). It seems that, following incubation in ascites, cyclodextrin-
complexes are more stable in terms of siRNA release in comparison with Lipofectamine® 
RNAiMAX complexes.  
 
Effect of nebulization on the physicochemical properties of siRNA complexes 
Table 1 depicts the average diameter of RNAiMAX/siRNA complexes before and after 
nebulization, using N/P ratios that lead to good siRNA complexation as determined above. For 
each of the studied N/P ratios, a minor increase in the average diameter was measured. 
Therefore, it seems that complexes are not majorly influenced by the nebulization process as 
no severe aggregation was seen for all the RNAiMAX/siRNA complexes. Importantly, the 
complexes remain in a nanometer size range following nebulization, which enables them to 
cross biological membranes and deliver their cargo into the desired cells28. Interestingly, 
nebulization also did not significantly affect the polydispersity index (PDI) of the complexes, 
providing further evidence that nebulization did not result in destabilization of the complexes. 
 
Table 1. Size measurements at different N/P ratios of the RNAiMAX/siRNA complexes 
prepared at a final amount of 50 pmol siRNA. The numbers in the table represent the 
hydrodynamic diameter (nm) ± SD. N=3.  
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N/P Non-Nebulizeda PDIb Nebulizeda PDIb 
2 179 ± 8 0.3 298 ± 5 0.5 
3 141 ± 1 0.4 193 ± 8 0.4 
4 152 ± 3 0.4 234 ± 5 0.4 
6 143 ± 7 0.3 216 ± 6 0.4 
8 121 ± 9 0.5 131 ± 7 0.4 
a Size in nanometer (nm) b Polydispersity index 
 
When ADM70/siRNA complexes were nebulized (Table 2), a more drastic effect was 
seen on the complex characteristics. Before nebulization, a decrease in size is visible for the 
complexes when the N/P ratio increases. It seems that a higher amount of ADM70, relative to 
the amount of siRNA, enables the formation of a smaller complexes. After nebulization, 
however, a substantial increase in the average diameter can be observed for the different N/P 
ratios. The largest increase following nebulization of complexes was seen for N/P ratio 10, 
resulting in micrometer sized aggregates. This size increase implies a form of instability of the 
ADM70 complexes that was not observed for the Lipofectamine® RNAiMAX complexes.  
 
Table 2. Size measurements at different N/P ratios of the ADM70/siRNA complexes. The 
numbers in the table represent the hydrodynamic diameter (nm) ± SD. N=3. 
N/P ratio Non-Nebulizeda PDIb Nebulizeda PDIb 
4 452 ± 14 0.3 763 ± 11 0.4 
6 315 ± 7  0.4 443 ± 22 0.4 
8 268 ± 8 0.4 919 ± 28 0.4 
10 209 ± 12 0.4 1360 ± 238 0.3 
a Size in nanometer (nm) b Polydispersity index 
 
Also when the charge of the complexes was determined, a difference can be seen before 
and after nebulization. Table 3 shows that for RNAiMAX/siRNA complexes, a clear trend of 
decrease in zeta potential can be observed for each N/P ratio. As the zetapotential becomes 
more negative, we hypothesize that this decrease is highly likely attributed to the rearrangement 
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of siRNA on the surface of the complexes, due to the friction or pressure applied during 
nebulization. However, it is important to notice that the complexes are still positively charged 
after nebulization, enabling interaction with the negatively charged cell membrane29.    
 
Table 3. Zeta potential measurements at different N/P ratios of the RNAiMAX/siRNA 
complexes. The numbers in the table represent the mean zeta potential ± SD. N=3. 
N/P Non-Nebulizeda Nebulizeda 
2 25 ± 3 19 ± 1 
3 38 ± 1 15 ± 1 
4 43 ± 2 22 ± 4 
6 44 ± 1 27 ± 2 
8 41 ± 1 25 ± 2 
a Zeta Potential in millivolt (mV) 
 
Also for ADM70/siRNA complexes, a decrease in zetapotential is observed after 
nebulization (Table 4). Again, we hypothesize that a rearrangement of siRNA in the 
cyclodextrine complexes occurs as a result of the friction or pressure applied during 
nebulization. It should be noted, however, that the complexes shift from a positive charge before 
nebulization to being negatively charged. This indicates that siRNA migrated to the surface of 
the cyclodextrine complexes during nebulization, possibly lowering the protection of the 
siRNA by the carrier. Also, the negative charge of the complexes might lower the interaction 
with cells and subsequent intracellular uptake. Taken together, both sort of complexes seem to 
be stable in a size range that enables them to cross biological membranes before and after 
nebulization. However, the drop in zeta potential following nebulization of the ADM70/siRNA 
complexes could possibly influence the transfection efficiency.  
 
Table 4. Zeta potential measurements at different N/P ratios of the ADM70/siRNA 
complexes. The numbers in the table represent the mean zeta potential ± SD. N=3. 
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N/P ratio Non-Nebulizeda Nebulizeda 
4 13 ± 9 -20 ± 4 
6 26 ± 2 -26 ± 2 
8 30 ± 1 -17 ± 2 
10 33 ± 1 -9 ± 3 
aZeta potential in millivolt (mV) 
 
Dose-dependent transfection efficiency of siRNA complexes 
 Initially we performed an optimization experiment to determine the suitable 
concentration of siRNA that induces gene silencing without causing toxicity. The N/P ratio of 
Lipofectamine® RNAiMAX/siRNA and ADM70/siRNA complexes was kept at 3 and 6 
respectively, being the first N/P ratio that fully complexed the siRNA as determined from 
Figure 1. For Lipofectamine® RNAiMAX complexes, increasing siRNA concentrations from 
1 to 10 pmol lead to an efficient downregulation of luciferase of around 80%. However, for the 
wells treated with 25 and 50 pmol of siRNA a clear decrease in the bioluminescence of the 
control siRNA was noticeable. This is an indication for toxicity which is probably attributed to 
the presence of a high concentration of siRNA or Lipofectamine® RNAiMAX. Thus 
RNAiMAX/siRNA complexes of 25 and 50 pmol were not considered for further experiments. 
For the cells treated with negative control ADM70/siRNA complexes (Figure 2B), no 
clear decrease in bioluminescence is noticeable, even not for the higher siRNA concentration.  
This low toxicity profile of the cyclodextrines could highly likely be the result of the 
amphiphilic structure as well as the presence of cationic clusters and hydrogen bonding thiourea 
groups, as demonstrated before21,23,30. It should be noted, however, that the cyclodextrines only 
result in a high amount of luciferase downregulation starting from 25 and 50 pmol siRNA. 
Therefore, it seems that the cyclodextrines used in this study need a 10-fold higher 
concentration of siRNA, to result in comparable levels of downregulation efficiency as  
Lipofectamine® RNAiMAX lipoplexes. 
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 Figure 2. Bioluminescence of SKOV-3 cells treated with RNAiMAX/siRNA lipoplexes (A) 
and ADM70/siRNA complexes (B) containing negative Control siRNA (dark grey bars) 
or luciferase siRNA (light grey bars) following four hours of incubation in Opti-MEMTM. 
Data are expressed as the average (± SD) from three independent transfection 
experiments. 
 
Effect of nebulization on the transfection efficiency of siRNA complexes 
Since nebulization has been proposed as a strategy to deliver chemotherapeutic drugs in 
the treatment of PC, we tested the transfection efficiency of the studied formulations after 
nebulization. DLS results have already shown an increase in hydrodynamic diameter of the 
lipoplexes, together with a drop in zetapotential. This raised the question if the transfection 
efficiency of the particles would still be sufficient after nebulization, since uptake and 
subsequently transfection efficiency are size and charge dependent19. 
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Figure 3. Percentage downregulation in SKOV-3 cells treated with by non-nebulized 
(dark grey bars) and nebulized (light grey bars) RNAiMAX/siRNA lipoplexes (N/P ratio 
3) (A) and ADM70/siRNA complexes (N/P ratio 6) (B) following four hours of incubation 
in Opti-MEMTM. Data are expressed as the average (± SD) from three independent 
transfection experiments. 
 
 Figure 3A demonstrates that a significant decrease in transfection efficiency is only 
observed for RNAiMAX/siRNA complexes delivering 1 pmol and 2 pmol of siRNA, whereas 
no significant difference was observed when 5 pmol and 10 pmol siRNA was present. 
Apparently, the destabilization of complexes does change transfection efficiency at lower 
siRNA concentrations, but can be overruled by administering a larger amount of the complexes 
onto the cells. For the ADM70/siRNA complexes (Figure 3B), again for the low amounts of 
siRNA (i.e. 5 and 10 pmol) a low transfection efficiency was noticeable, whereas for the high 
amounts of siRNA, the transfection is higher ranging from 65% to 80% downregulation. After 
nebulization, the downregulation is not statistically different, although the larger error bars 
demonstrate the appearance of more variability in the transfection results. This result was rather 
unexpected since zeta potential measurements demonstrated a negative zeta potential for these 
complexes after nebulization. It should be noted, however, that the complexes used for 
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transfection experiments were administered in Opti-MEMTM which could lead to different size 
and zeta potential values than presented in Table 3 and 4 respectively.  
Several mechanisms can be responsible for the small loss in transfection efficiency. First 
of all, it is possible that the complexes lose some of their stability during nebulization. This 
stability is an important determinant for the overall transfection efficiency and may be 
hampered by premature siRNA release and aggregate formation19,28. As the siRNA 
concentration was changed by adding different volumes of the nebulized complexes, the effect 
of nebulization on the complex efficiency was expected to be comparable for all siRNA 
amounts that were delivered. If some siRNA is released during nebulization, however, it can be 
expected that this effect is larger for the lower amounts of siRNA (i.e. 1 and 2 pmol) as the 
threshold for a sufficient siRNA concentration might no longer be reached. The decrease in 
transfection efficiency may also be attributed to the change in structure of some siRNA 
molecules due to the pressure applied, as suggested for pDNA in literature26. Again, however, 
it is a possibility that when higher volumes (i.e. more complexes) are added on the cells, the 
amount of siRNA entering the cell and able to exert its function is still sufficient which can lead 
to non-significant decrease in transfection efficiency.  
 
Effect of ascites fluid on the transfection efficiency of siRNA complexes 
As mentioned earlier, one of the aims of this work is to evaluate the biological activity 
in a relevant biological fluid for peritoneal carcinomatosis. Therefore, the ability of the siRNA-
complexes to downregulate luciferase expression, following 1 hour incubation in ascites fluid, 
was determined (Figure 4).  
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Figure 4. Percentage downregulation in SKOV-3 cells treated with RNAiMAX/siRNA 
lipoplexes (N/P ratio 3) (A) and ADM70/siRNA complexes (N/P ratio 6) (B) in Opti-
MEMTM (dark grey bars) and following 1 hour incubation in ascites fluid (light grey bars). 
Data are expressed as the average (± SD) from three wells in the same transfection-
experiment. 
  
Both for RNAiMAX/siRNA complexes and ADM70/siRNA complexes, the two highest 
siRNA doses were chosen as these were not influenced by the nebulization of the complexes. 
In opti-MEMTM, both type of complexes again show good transfection efficiencies. Following 
exposure to ascites fluid, however, a clear decrease in the transfection efficiency can be noticed 
for all amounts of siRNA. For the RNAiMAX/siRNA complexes, about 40% of downregulation 
remains. For ADM70/siRNA complexes, however, the transfection efficiency drops to less than 
20% for 50 pmol of siRNA and even to 0% when 25 pmol of siRNA is delivered. The premature 
release of siRNA could  be considered as a possible reason for the decrease in transfection 
efficiency, although gel electrophoresis did not show a high amount of free siRNA in ascites 
fluid (see Figure 1).   
Another possible reason for the decrease in transfection efficiency in ascites fluid is a 
diminished uptake of the complexes. We have demonstrated before that incubation in ascites 
fluid lowers the transfection efficiency of DOTAP/DOPE siRNA complexes by lowering the 
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cellular uptake of the complexes4,19. Binding of negatively charged proteins present in ascites 
fluid is most likely responsible for the observed effect. Alternatively, the formed ‘protein 
corona’ can also interfere with the intracellular pathways followed by the nanoparticles, leading 
to non-productive siRNA delivery, as we observed for lipoplexes composed of DOTAP and 
cholesterol (non-published data).  
 
Combined effect of nebulization and the presence of ascites fluid on the transfection 
efficiency of siRNA complexes 
In the eventual therapeutic application, the complexes will first be nebulized and then come in 
contact with the peritoneal tumor nodules and the ascites fluid. Therefore, we tested how the 
combination of nebulization and the subsequent incubation in ascites fluid affected the 
transfection efficiency of siRNA complexes. For both RNAiMAX/siRNA complexes and 
ADM70/siRNA complexes, the highest siRNA dose was chosen. Figure 5 A demonstrates that 
for nebulized RNAiMAX/siRNA complexes, the incubation in ascites fluid (grey bars) does 
not further decrease the percentage of downregulation when compared to nebulized complexes 
administered in opti-MEMTM (black bars). For nebulized ADM70/siRNA complexes (Figure 5 
B), however, the presence of ascites fluid again severely decreased the downregulation 
efficiency, in agreement with the effects observed on non-nebulized ADM70/siRNA 
complexes. The presence of ascites fluid thus strongly affects the efficiency of 
cyclodextrine/siRNA complexes. It should be noted, however, that large volumes of ascites 
fluid are only expected in patients that are in an advanced stage of peritoneal carcinomatosis. 
Currently, we cannot rule out the possibility that the lower amount of ascites fluid, present in 
patients that receive the PIPAC procedure, could have a less drastic effect on the transfection 
efficiency of the ADM70/siRNA complexes.    
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Figure 5. Percentage downregulation in SKOV-3 cells treated with nebulized 
RNAiMAX/siRNAlipoplexes (N/P ratio 3) (A) and nebulized ADM70/siRNA complexes 
(N/P ratio 6) (B) in Opti-MEMTM (dark grey bars) and following 1 hour incubation in 
ascites fluid (light grey bars). Data are expressed as the average (± SD) from three wells 
in the same transfection-experiment. 
 
CONCLUSION 
Administration of siRNA complexes in the peritoneal cavity has the potential to treat 
peritoneal carcinomatosis. The nebulization of complexes in the peritoneal cavity has clear 
advantages such as a more even spreading of the complexes in the large surface area of the 
peritoneum. It might, however, also affect the transfection efficiency of complexes due to the 
high pressure applied during the procedure. We have demonstrated that both lipid-based carriers 
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(Lipofectamine® RNAiMAX) and polymeric cyclodextrines (ADM70) have the potential to 
successfully administer siRNA to ovarian cancer cells. Lipoplexes, however, reached a good 
transfection efficiency already at a 10 times lower siRNA dose. Upon nebulization of the 
complexes, a minor decrease in transfection efficiency was observed, especially for the lower 
siRNA concentrations. Possible reasons for this observation are the increase in size and 
decrease in zeta potential observed for the complexes at different N/P ratios. When higher 
amounts of siRNA (i.e. more complexes) were added on the cells, however, the small decrease 
in transfection efficiency could be overcome. The presence of ascites fluid, however, had a 
more drastic effect on the transfection efficiency, especially for the cyclodextrin/siRNA 
complexes. The loss in transfection efficiency for cyclodextrine/siRNA complexes can most 
likely be attributed to the formation of a protein corona around the nanoparticles, interfering 
with cellular uptake or the intracellular delivery pathway of siRNA. Overall, however, we 
conclude that nebulization is a promising administration route for siRNA complexes to the 
peritoneal cavity, providing the complexes remain stable in ascites fluid.   
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CAPTIONS TO FIGURES 
Figure 1. Agarose gel electrophoresis of (A) RNAiMAX/siRNA complexes and (B) 
ADM70/siRNA complexes prepared at different N/P ratios as depicted above each well. The 
final amount was 10 pmol siRNA/well. A 100 basepair (bp) ladder is positioned in the last well. 
(C) and (D) represent the RNAiMAX/siRNA and ADM70/siRNA complexes following 
incubation in ascites fluid. (E) represent ascites fluid alone (first lane) and free siRNA (second 
lane). Open circle, arrowhead and asterisk point to the position of complexes, ascites fluid and 
free siRNA respectively.    
 
 
 Figure 2. Bioluminescence of SKOV-3 cells treated with RNAiMAX/siRNA lipoplexes (A) 
and ADM70/siRNA complexes (B) containing negative Control siRNA (dark grey bars) or 
luciferase siRNA (light grey bars) following four hours of incubation in Opti-MEMTM. Data 
are expressed as the average (± SD) from three independent transfection experiments. 
 
 
Figure 3. Percentage downregulation in SKOV-3 cells treated with by non-nebulized (dark grey 
bars) and nebulized (light grey bars) RNAiMAX/siRNA lipoplexes (N/P ratio 3) (A) and 
ADM70/siRNA complexes (N/P ratio 6) (B) following four hours of incubation in Opti-MEM 
TM. Data are expressed as the average (± SD) from three independent transfection experiments. 
 
Figure 4. Percentage downregulation in SKOV-3 cells treated with RNAiMAX/siRNA 
lipoplexes (N/P ratio 3) (A) and ADM70/siRNA complexes (N/P ratio 6) (B) in Opti-MEM TM 
(dark grey bars) and following 1 hour incubation in ascites fluid (light grey bars). Data are 
expressed as the average (± SD) from three wells in the same transfection-experiment. 
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Figure 5. Percentage downregulation in SKOV-3 cells treated with nebulized 
RNAiMAX/siRNAlipoplexes (N/P ratio 3) (A) and nebulized ADM70/siRNA complexes 
(N/P ratio 6) (B) in Opti-MEMTM (dark grey bars) and following 1 hour incubation in 
ascites fluid (light grey bars). Data are expressed as the average (± SD) from three wells 
in the same transfection-experiment. 
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Table 1. Size measurements at different N/P ratios of the RNAiMAX/siRNA complexes 
prepared at a final amount of 50 pmol siRNA. The numbers in the table represent the 
hydrodynamic diameter (nm) ± SD. N=3.  
N/P Non-Nebulizeda PDIb Nebulizeda PDIb 
2 179 ± 8 0.3 298 ± 5 0.5 
3 141 ± 1 0.4 193 ± 8 0.4 
4 152 ± 3 0.4 234 ± 5 0.4 
6 143 ± 7 0.3 216 ± 6 0.4 
8 121 ± 9 0.5 131 ± 7 0.4 
a Size in nanometer (nm) b Polydispersity index 
 
Table 2. Size measurements at different N/P ratios of the ADM70/siRNA complexes. The 
numbers in the table represent the hydrodynamic diameter (nm) ± SD. N=3. 
N/P ratio Non-Nebulizeda PDIb Nebulizeda PDIb 
4 452 ± 14 0.3 763 ± 11 0.4 
6 315 ± 7  0.4 443 ± 22 0.4 
8 268 ± 8 0.4 919 ± 28 0.4 
10 209 ± 12 0.4 1360 ± 238 0.3 
a Size in nanometer (nm) b Polydispersity index 
Table 3. Zeta potential measurements at different N/P ratios of the RNAiMAX/siRNA 
complexes. The numbers in the table represent the mean zeta potential ± SD. N=3. 
N/P Non-Nebulizeda Nebulizeda 
2 25 ± 3 19 ± 1 
3 38 ± 1 15 ± 1 
4 43 ± 2 22 ± 4 
6 44 ± 1 27 ± 2 
8 41 ± 1 25 ± 2 
a Zeta Potential in millivolt (mV) 
 
Table 4. Zeta potential measurements at different N/P ratios of the ADM70/siRNA 
complexes. The numbers in the table represent the mean zeta potential ± SD. N=3. 
N/P ratio Non-Nebulizeda Nebulizeda 
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4 13 ± 9 -20 ± 4 
6 26 ± 2 -26 ± 2 
8 30 ± 1 -17 ± 2 
10 33 ± 1 -9 ± 3 
aZeta potential in millivolt (mV) 
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TOC 
This study demonstrates that nebulization is an interesting technique to distribute siRNA 
complexes into the peritoneal cavity, providing the complexes are stable in ascites fluid which 
might be present in the peritoneal cavity. The lipid-based RNAiMAX/siRNA complexes proved 
to be superior over polymeric siRNA cyclodextrin complexes at lower siRNA concentrations 
and in the presence of ascites fluid.  
 
 
 
